These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32162057)

  • 61. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
    Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
    Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ethanol decreases negative cell-cycle-regulating proteins in a head and neck squamous cell carcinoma cell line.
    Kornfehl J; Hager G; Gedlicka C; Formanek M
    Acta Otolaryngol; 2002 Apr; 122(3):338-42. PubMed ID: 12030586
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
    Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
    Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
    Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Further evidence that altered p16/CDKN2 gene expression is associated with lymph node metastasis in squamous cell carcinoma of the esophagus.
    Takeuchi H; Ozawa S; Ando N; Kitagawa Y; Mukai M; Ueda M; Kitajima M
    Oncol Rep; 2001; 8(3):627-32. PubMed ID: 11295092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
    Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
    Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
    Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
    J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Letter to the editor regarding "Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.".
    Liang R
    Cancer Lett; 2022 Feb; 527():191-192. PubMed ID: 35115094
    [No Abstract]   [Full Text] [Related]  

  • 78. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas.
    Park HW; Song SY; Lee TJ; Jeong D; Lee TY
    Oncol Rep; 2007 Jul; 18(1):267-72. PubMed ID: 17549378
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.